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tection rate. In a previous work we have described a procedure allowing an extensive
re-sequencing (by cycle sequencing, Applied Biosystems) of all exons and of the ad-
jacent intronic zones of CFTR (30 amplicons, each subjected to forward and reverse
sequencing), that can ﬁt in a 8× 12 (= 96-well) format, with simultaneous exami-
nation of 11 subjects (plus one blank). We are presenting here an almost fully auto-
mated version of this method, based on the combined use of a Hamilton 4-channels
StarLet robotics system and an Applied Biosystems ABI PRISM 3100 Avant genetic
analyzer (4-capillaries), with an analysis of time and costs of this automated proce-
dure and an assessment of its advantages. The CFTR complete scan of 11 subjects
actually starts the ﬁrst day with the assembly of the ﬁrst plate, followed by 13 days of
ABI PRISM time (in the meantime, all plates could be prepared and run one after the
other). By using our personalized CFTR-template, the large set of sequencing data
produced is easily processed by SeqScape software for sequence analysis (Applied
BioSystems). One additional day is then needed for software analysis of the last
plate. The limiting step in this process is the development of the electropherograms
by the 4-capillaries genetic analyzer, since approximately 80 hours are required for
a full analysis of 96 samples (forward and reverse, run in duplicate). A different
hardware conﬁguration (16-channels, instead of 4, for both instruments) markedly
reduces the overall time to 5 days, 3 of which of ABI PRISM time. The overall
cost for a complete CFTR scan by this automated method, including consumables
(tips, plates, capillary arrays) and reagents (Taq polymerase, POP-6 polymer and
BigDye terminators), is about 240 euros/subject. A very limited human involvement
is needed after robotics programming. The overall costs of this procedure, especially
if its high detection rate is taken into account, are comparable to those of other
scanning techniques and also of methods focused on limited number of mutations.
For a high productivity, the use of a 16-analytical channel instrument is advised.
S. P. was partially supported by a grant from “Associazione Laziale Fibrosi Cistica”.
P9 CYSTIC FIBROSIS MUTATIONS: GENOTYPE-PHENOTYPE
RELATIONSHIP IN PATIENTS DIAGNOSED BY NEONATAL
SCREENING
I. Tardivo1, A. Veljkovic1, C. Risso1, G. Restagno2, C. Mari2, A. Lezo1,
E. Bignamini1. 1Pediatric CF Center Piedmont and Valle d’Aosta – OIRM – Turin,
Italy; 2Molecular Genetics Service – OIRM – Turin, Italy
Although there are more than 1000 mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR) gene, most of them are uncommon and only limited
informations exist regarding genotype–phenotype correlation. In this survey we
retrospectively examined our screened population of CF patients, diagnosed from
July 2000 to May 2007, in order to investigate the relationship between their clinical
status and genotype.
Patients were classiﬁed depending on the CFTR mutation class on each chromo-
some. They were subsequently categorized into two groups according to whether the
CFTR protein reached the epithelial surface (Group 2: at least one mutation class
type III-IV-V) or not (Group 1: type I or II mutation class on both chromosome).
We considered age, sex, neonatal screening results, sweat test values, pancreatic
sufﬁciency and Pseudomonas aeruginosa ﬁrst infection.
From July 2000 to May 2007 we diagnosed 73 patients (40 females and 23 males)
for whom it was possible to identify both CFTR mutations; they actually have a
mean age of 3.92 years. We identiﬁed in Group 1 52 patients (27 M and 25 F)
with a mean age of 3.75 years and in Group 2 21 patients (6M and 15 F) with a
mean age of 4.3 years. Six patients of Group 1 (8.6%) vs 3 patients (7%) of Group
2 resulted as false negative at the neonatal screening. The mean sweat test value
was 100.17 mEq/l (IC 95% range 86.28–114.06) for the ﬁrst group of patients and
84.41 mEq/L (IC 95% range 67.93–100.89) for the second group with p: 0.18.
With regard to the pancreatic status 35 patients out of 52 (67.3%) in Group 1 have
pancreatic insufﬁciency vs 2 patients out of 21 (9.5%) in Group 2 (p< 0.05). Thirty-
three patients of our population have had ﬁrst Pseudomonas aeruginosa infection:
27/52(51.9%) in Group 1 of patients and 6/21 (28.5%) in Group 2. The mean age
of acquisition was for Group 1 1.12 years vs 1.36 years for Group 2 (p: 0.6), but the
patients who are actually negative for Pseudomonas aeruginosa infection are 25/52
in the ﬁrst group with a mean age of 2.8 years and 15/21 in the second group with
a mean age of 4.01 years (p: 0.08).
Conclusions: screening diagnosed patients belonging to ﬁrst and second class
mutation genotype present an earlier Pseudomonas aeruginosa infection in respect
of patients group having other mutations (class type III-IV-V).
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Neonatal screening for CF has been introduced in July 2000 as investigational
procedure in Piedmont Region (Italy). Until May 2007 96 children have been
diagnosed at our CF Center: 19 patients out of 96 resulted false negative at
the neonatal screening and therefore were diagnosed by symptoms. The genetic
diagnosis is performed at ﬁrst instance by the analysis of the 31 most common
mutations using the OLA-PCR-SCS method and then, if necessary, by the whole
gene scan with DHPLC method. In 45 patients out of 96 it has been necessary
to apply DHPLC: in 15 patients out 45 the neonatal screening has resulted false
negative. Using DHPLC both mutations were detected in 30 out of 45 patients;
in 15 cases only one mutation (13 cases) or no mutation (2 cases) were found: 7
patients of this group had been false negative at neonatal screening.
Mutations detected by DHPLC belong to mutation class I in 45.83% of cases, to
class IV in 16.67% and to class III in 4.17% of cases. The table shows the class
of mutation detected in our population with OLA and DHPLC.
Mutation class Frequency Percentage Cumulative percentage
II 111 58.73 58.73
I 30 15.87 74.60
N 24 12.70 87.30
IV 17 8.99 96.30
V 5 2.65 98.94
III 2 1.06 100.00
Total 189 100.0
Conclusions: neonatal screening has permitted to modify patient’s population,
detecting also uncommon mutations; furthermore neonatal screening seems to be
more sensitive for patients with mutation class I or II.
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Background: Mutations in the Cystic Fibrosis Transmembrane Conductance Reg-
ulator (CFTR) gene cause Cystic Fibrosis (CF). They are also involved in other
diseases, such as idiopathic pancreatitis.
Case-report: We present a case-report of a family composed by four per-
sons in which genetic analysis showed an identical homozygous genotype
(D1152H/D1152H) in the mother and her two sons, associated with different clinical
expressions. In fact, only the second born male had a pathological sweat test and a
diagnosis of a mild form of classic CF, with a minimal lung disease and pancreatic
sufﬁciency. On the other hand, the mother and the ﬁrst born female had an exclusive
pancreatic involvement and signs of chronic pancreatitis: the mother had only one
clinical expression in her life referable to an acute pancreatitis, whereas her daughter
was affected by recurrent episodes of pancreatitis conﬁned to her ﬁrst years of life.
Both patients showed normal chloride values at the sweat test.
Conclusions: This report conﬁrms the difﬁculties for diagnosing atypical CF
and emphasizes the role of CFTR mutations in the pathogenesis of idiopathic
pancreatitis. In particular, D1152H mutation is strictly associated with atypical
expression of CF and pancreatic sufﬁciency. The phenotypic variability seen in this
family could be determined by other non-CFTR genes acting as possible modiﬁers
of disease expression; alternatively, gender differences may be involved in the
determination of CF phenotype, as suggested by several observations in literature.
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Background: Non-classic Cystic Fibrosis (CF) currently represents a difﬁcult entity
to deﬁne for clinicians, especially at the early stage of the disease, because of
unusual presentation and/or late onset of symptoms. Moreover, the sweat test may
show border-line or normal values and the diagnosis is mainly based on clinical
features and follow-up. Genetic analysis of the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene may identify one severe or mild mutation in
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trans with a 5 thymidines (5T) sequence within the intron 8 Splice Variant (IVS8)
region. 5T is responsible of an exacerbated skipping of exon 9, decreasing the
functional product levels. It has been demonstrated that 5T phenotypic expression
is inﬂuenced by another adjacent polymorphic region, constituted by 9 to 13 TG
repeats. In particular, 5T/TG13 combination was found only in affected subjects.
Case Report: We report a case regarding two sisters, aged 23 and 18 years,
carriers of the F508del mutation associated with the 5T/TG13 combination. DHPLC
investigation did not detect a second mutation. Both sisters present mild pulmonary
symptoms started in puberty, bronchiectasis, pancreatic sufﬁciency and border-line
chloride values at the sweat test. However, they differ because the elder patient has
more evident bronchiectasis, and she also presents pansinusitis, a positive sputum
culture and a slightly reduced FEV1.
Conclusions: The natural history of non classic CF is poorly understood. It may be
asymptomatic for years but a signiﬁcant lung involvement may occur, as seen in the
elder sister. This ﬁnding suggests that a prevention therapy could be necessary also
in mild, non classic CF and an early diagnosis may prevent the organ deterioration,
as in the younger sister. Early diagnosis may be supported by TG repeats testing in
individuals carrying the 5T variant; in fact, our report conﬁrms that the presence of
5T allele, in trans with a severe CFTR mutation, is associated with non classic CF
and that TG13 variant acts as a real mild mutation, enhancing the 5T penetrance
and determining the onset of a mild symptomatology in all patients.
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Introduction: In recent years, an increasing number of subjects bearing “atypical”
forms of cystic ﬁbrosis (CF) associated with normal sweat chloride concentrations
has been described.
Objective: We report a case of an atypical form of CF observed in two sisters with
F508del/G576A + R668C complex CFTR genotype.
Methods: These patients were ﬁrst examined for a panel of 56 CF mutations with
Inno-Lipa reverse dot blot procedure (Innogenetics Belgium) and later with DGGE
of all exons of the CFTR gene using primers and the conditions described elsewhere
(Fanen P, et al. 1992. Genomics 13, 770–776; Costes B, et al. 1993. Hum Mol Genet
2, 1209–1213) followed by sequencing analysis to characterize the mutations.
Case: A 6-year-old female with recurrent episodes of asthma exacerbation came
to the Southern Italy referral CF Centre in October 2006. She did not present
symptoms of pancreatic insufﬁciency. However, she was hetereozygous for F508del
with a normal sweat chloride test (38mEq/L). After scanning the whole CFTR gene
we individuated other mutations: G576A (exon 12) and R668C (exon 13). On the
basis of these results, her sister (5-year-old) affected by recurrent episodes of upper
airway infections was also examined. She showed the same CFTR genotype of her
sister, her sweat chloride values were also normal (31mEq/L).
Discussion and Conclusion: The G576A, originally listed as a neutral polymor-
phism in CF Genetic Analysis Consortium (www.genet.sikkids.on ca./cftr/) is a
missense mutation that causes CFTR exon 12 skipping (Pagani F, et al. 2003. Hum
Mol Genet 12, 1111–1120). More recently, studies documented this mutation in
adults with classic forms of CF (Bienvenu T, et al. 1997.Ann Genet 40, 5−9) and
in patients who have evidence of a clinical disease only in a subgroup of the organ
systems (Ravnik-Glavac M, et al. 2000. Pﬂugers Arch 439, 53−55; Pignatti PF,
1995. Mol Genet 4, 635–639). These non classic CF forms, including late-onset
pulmonary disease, bronchiectasis, congenital bilateral absence of vas deferens
or idiopathic pancreatitis were associated with the presence of the G576A allele
combined with the R668C polymorphism. Our ﬁndings suggest that our patients
have the same described genetic arrangement but a longer period of follow-up is
needed to get deﬁnitive conclusions. How can we manage these cases in childhood?
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A 26-year-old subject with azoospermia was referred to our Center. The genetic
test at the ﬁrst level of screening showed heterozygosity for F508del.
From the history, symptoms suggestive of CF were present (three episodes of serious
dehydration, bronchopulmonary pathology, easy to become tired) therefore the sweat
test was performed and resulted pathological (Cl− 92/94), leading to a diagnosis
of CF.
In order to identify the second mutation the analysis of the entire coding sequence
of the CFTR gene was performed and we identiﬁed the mutation E831X, a G to T
transition at position 2623 in exon 14a. This mutation has been reported in Cystic
Fibrosis Database two cases (Ferec et al 1992).
General conditions of our patient are good, good nutritional status, PS and mild
lung disease.
Because exon 14a is the subject of alternative splicing (Hull et al., 1994) and
the mutation E831X is at the ﬁrst base of this exon we suppose that the mutation
caused a new site of splicing and increase its alternative splicing. Such a by-pass of a
premature termination codon has been shown to ameliorate the disease phenotype in
other clinical conditions (Morisaki et al., 1993; Ginjaar et al., 2000; Su et al., 2000).
Accurate history, sweat test and mutation analysis of CFTR gene have permitted to
reﬁne the diagnosis of CF in an azoospermic adult subject.
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A signiﬁcant percentage of CF alleles (ranging from 4 to 10%) remain unidentiﬁed
in most population, even after extensive studies of the CFTR gene by PCR based
procedure. At present time, CFTR mRNA analysis represents more a research tool
for the identiﬁcation of unknown molecular defects of the CFTR gene in speciﬁc
rare cases than a routine approach to complete a diagnostic procedure. In particular
mRNA analysis may allow researchers to establish the pathogenic role of sequence
variations not yet deﬁned like speciﬁc splicing defects. The results of our screening
for CFTR gene at DNA level, by DHPLC and MLPA analyses showed a mutation
detection rate of 94.4%. After this analysis, in our patients, 81 alleles (6%) were
still unknown. Aim of this work was to evaluate the role of the CFTR analysis at
mRNA level as a diagnostic method for the characterization of molecular defects
in patients affected by a classic form of CF, who still had one or two unidentiﬁed
alleles after an extensive analysis at DNA level. RNA was extracted with TRIzol
reagent, from nasal epithelial cells and collected using cyto-brush from 7 CF patients
and 3 non-CF controls. First strand cDNA was synthesized using hexanucleotide
primers and high capacity cDNA Archive kit. The cDNA was ampliﬁed in six
overlapping fragments spanning the entire gene and then visualized on agarose
gel for identifying large deletion/insertion and the product of possible alternatives
splicing; each fragment was next sequenced.
Disease-related mutations, not detected by DHPLC technique, were identiﬁed in two
patients; mRNA analysis performed on two other related patients with a deletion of
exon 2 at DNA level showed two novel transcription products carrying a deletion
of exon 2−3 and an insertion of intron sequence of about 80bp near exon 6b,
respectively. Two patients had low level of mRNA product and have to be analyzed
by quantitative technique. One patient showed a normal proﬁle. In conclusion our
data suggest that the defects at RNA level could explain the pathogenic role of
abnormal mRNA products in Cystic Fibrosis onset.
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Introduction: More than 1200 mutations and 200 polymorphisms have been
described for CFTR gene. Prenatal Diagnosis of Cystic Fibrosis (CF) must be
proposed to couples in which both partners are carriers of CFTR mutations and
thus the fetus is at one in four (1/4) risk of being affected.
Since 1989 the Centro di Riferimento Regionale Toscano per la Diagnosi Genetica
di Fibrosi Cistica has performed the characterization of CF patients together with
prenatal diagnosis for at-risk couples. The steps to be followed with prenatal
diagnosis will be as follows:
• Pre-test genetic counselling: to be performed before invasive procedures (am-
niocentesis or CVS) in order to advise the couples about the risk of prenatal
sampling and the accuracy of the genetic test for the diagnosis of CF.
• Post-test genetic counselling: to be performed in order to illustrate the results
obtained from the genetic test.
The at-risk couples are followed by a team composed by physicians, genetic
counsellor and other specialists.
Methods: Prenatal specimen types include both amniocytes and chorionic villi.
On the fetus’ DNA known mutations are detected by direct sequencing or OLA-
PCR; when mutations causing familial CF are unknown, CFTR gene is investigated
